LINDSAY MUELLER: Open Payments
NPI 1841720653 · INDIANAPOLIS, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,345 in 69 payments from 18 companies in 2025. Trend: 2023 $2,826 · 2024 $2,738 · 2025 $1,345
Food & beverage: $1,345
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 20 | $371 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $222 |
| Janssen Biotech, Inc. | 9 | $180 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $103 |
| Regeneron Healthcare Solutions, Inc. | 4 | $97 |
| Phathom Pharmaceuticals, Inc. | 4 | $54 |
| GENZYME CORPORATION | 1 | $48 |
| Ipsen Biopharmaceuticals, Inc | 2 | $39 |
| Gilead Sciences, Inc. | 2 | $34 |
| QOL Medical, LLC | 2 | $33 |
Products named: RINVOQ, TREMFYA, ENTYVIO, DUPIXENT, XIFAXAN, VOQUEZNA, EOHILIA, IQIRVO.
Industry payments across IN — which companies pay providers there.
